Adar Poonawalla, CEO of Serum Institute of India, which is leading in the creation of Coronavirus in India, says that vaccine work is slow in India but it will be completely safe for public use whenever completed.
While more than 120 Corona Vaccine trials are underway worldwide, companies in India are also making efforts throughout the day to provide the vaccine. The Pune-based Serum Institute of India, which has been at the forefront of making the Corona vaccine among indigenous companies, says that by early April 2021 in India there will be an ‘Approved Corona Vaccine’ which will be fully Will be safe for public use.
Significantly, Serum Institute is the world’s largest vaccine manufacturer by volume (Worlds Largest Vaccine Manufacturers By Volume). On the other hand, the Wall Street Journal’s top research and brokerage firm Bernstein Research has said in a report published on August 27 that the Serum Institute of India is very close to making Corona the safest vaccine.
4 companies lead the vaccine race
There are four candidate companies globally that are at the forefront of delivering a safe approved and fully prepared vaccine for public use by the end of 2020 or early 2021. At the same time through partnership, two companies in India are also increasingly working on the viral vector vaccine of Oxford and the protein subunit vaccine of Novavax. The Bernstein report clearly states that one or possibly both vaccine companies will receive tremendous profits in the coming months, depending on the current capabilities of these two vaccines and the time they are approved, the ability to fight the virus and the cost of the vaccine. Can give.
Successful testing in the early stages
On the basis of data from the first and second phase of vaccine trials of both companies, the Bernstein report has also succeeded in developing vaccine protection and immunity against viruses. The report states that the way things are now looking, two doses of both vaccines will begin to develop immunity against the virus in 21 to 28 days. This report from a prestigious institution like the Wall Street Journal raises expectations about India’s ability to deliver vaccines globally. According to the report, the Serum Institute of India can supply 60 crores (600 million) doses in 2021 and around 100 crores (1 billion) doses in 2022 of which 40 to 50 crore (400 to 500 million) doses by 2021 in India alone. May be used in The report estimates that the vaccine will be shared between the government and private markets in a ratio of 55:45 respectively.
These domestic companies are also making vaccines
The Serum Institute has stated that it will price its vaccine at $ 3 per dose. But apart from the Serum Institute, there are at least 3 companies which are involved in making vaccines in India. Among these Indian pharma companies, Zydus, Bharat Biotech and Biologie E are listed. All three companies are working on their own vaccine and are currently in Phase 1 and 2 of the trial.
Serum medicine to every other child in the world
India produces about 2.3 billion different vaccine supplements every year, among biotech, biological and some small players. India produces around 200 to 300 crores (2-3 billion) different vaccines and doses annually on the basis of a few other small companies including Serum Institute, Zydus, Bharat Biotech and Biologie E. Serum alone is the world’s largest manufacturer of vaccines with a dosage of 150 million (1.5 billion). Globally, two out of every three children receive a vaccine or supplements manufactured by the Serum Institute. According to Bernstein, the total vaccine market in India is expected to be 600 crore ($ 6 billion) in FY 2021-22.